Brain Delivery
Brain Delivery - Related Videos
02:58
Convection-Enhanced Delivery of Antibodies into a Mouse Brain
0 Views •
2025
This video demonstrates a convection-enhanced delivery (CED) technique for antibody delivery into the mouse brain. The skull of an anesthetized mouse is exposed, and a burr hole is created at the target area for antibody delivery. A step catheter containing antibodies is inserted at the target site, and via an infusion pump, a pressure gradient is created to deliver antibodies at a controlled rate.
04:05
Intranasal Delivery of siRNA to the Mouse Brain Using a Positioning Device
0 Views •
2025
Source: Ullah, I., et.al. A Positioning Device for the Placement of Mice During Intranasal siRNA Delivery to the Central Nervous System. J. Vis. Exp. (2019)This video demonstrates a precise intranasal administration technique for delivering neuron-targeting peptide-siRNA complexes to the mouse brain using a specialized positioning device. Anesthetized mice are secured in a head-down-and-forward position to optimize siRNA inhalation while preventing lung drainage. The targeting peptide...
02:14
Delivery of a Traumatic Brain Injury to a Mouse Brain
0 Views •
2025
This video demonstrates the delivery of Traumatic Brain Injury (TBI) in mice. After exposing the skull, the TBI site is marked. The mouse is then positioned under the TBI device. The impact is delivered by lifting the metal rod and allowing it to drop freely onto the impactor, which is in contact with the skull.
02:24
Microinjection-Based Delivery of a Therapeutic Agent into an Awake Rodent Brain
0 Views •
2025
Source: Poland, R. et al. Rodent Brain Microinjection to Study Molecular Substrates of Motivated Behavior. J. Vis. Exp. (2015)In this video, a water-filled microinjection setup consisting of a syringe and microinjector tubing is used for precise drug delivery. A rat with a pre-implanted guide cannula undergoes targeted brain microinjection, enabling accurate administration of therapeutic agents in awake animals with minimal tissue damage.
07:34
Delivery of Antibodies into the Brain Using Focused Scanning Ultrasound
0 Views •
Cited by 6 •
2020
Presented here is a protocol to transiently open the blood-brain barrier (BBB) either focally or throughout a mouse brain to deliver fluorescently-labeled antibodies and activate microglia. Also presented is a method to detect the delivery of antibodies and microglia activation by histology.
FAQs
Receptor-mediated transport uses interactions between therapeutic molecules and receptors associated with the blood-brain barrier to support movement into the central nervous system. This approach can improve exposure without relying solely on nonspecific barrier disruption. Its value is especially relevant when researchers need to direct drugs, biologics, vaccines, or immune-modulating agents toward affected neural tissues.
Changing the properties of a therapeutic molecule can help it interact more effectively with the blood-brain barrier or remain suitable for transport into neural tissue. The overview identifies molecular modification as one strategy for improving access. Better entry may increase the amount of intervention reaching the target site while potentially reducing unnecessary systemic exposure.
Carriers can package therapeutic substances and support their movement across the blood-brain barrier. This is useful for agents whose properties otherwise limit central nervous system access. Carrier-based approaches may also help direct treatment toward affected tissues, although strategies that temporarily alter barrier function must preserve the barrier’s protective role in the nervous system.
Effective strategies must increase central nervous system exposure without compromising the blood-brain barrier’s protective function. Receptor-mediated transport, molecular modification, and carrier systems seek to improve access directly, whereas temporary barrier alteration requires particular attention to preservation. This balance matters because greater delivery is useful only when it supports treatment without undermining neural protection.
Researchers first identify the therapeutic category, such as a drug, biologic, vaccine, or immune-modulating agent, and then select an access strategy. Options include receptor-mediated transport, molecular modification, or carrier packaging. They must also consider whether temporary barrier alteration is appropriate and assess whether the approach improves neural exposure while limiting systemic distribution.
It is particularly relevant when disease processes involve the central nervous system, including neuroinflammation and viral or bacterial infections. Directing interventions toward affected tissues can support more precise investigation of immune activity and infectious disease in the brain. The same delivery principles also apply to central nervous system diseases where limited access restricts therapeutic exposure.
Improved delivery can increase therapeutic effectiveness by raising exposure at affected central nervous system tissues. It may also reduce systemic exposure, allowing researchers to investigate more targeted interventions rather than distributing the agent broadly throughout the body. In immunology and infection studies, this can help evaluate treatments or immune-modulating approaches at relevant neural sites.